Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a ...

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...